<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925935</url>
  </required_header>
  <id_info>
    <org_study_id>AB-205-001</org_study_id>
    <nct_id>NCT03925935</nct_id>
  </id_info>
  <brief_title>Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation</brief_title>
  <official_title>A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiocrine Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Angiocrine Bioscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin
      lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without
      radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205
      infusion following autologous stem cell transfusion on Day 0.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>AB-205 dose escalation based on safety.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and duration of grade ≥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea.</measure>
    <time_frame>Day 0 to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>First of three consecutive days after ASCT of absolute neutrophil count (ANC) &gt; 500/μL</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>First of seven consecutive days after ASCT of platelet count ≥ 20,000/μL without transfusion support</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lymphoid recovery</measure>
    <time_frame>14, 28 and 100 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>100 and 365 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>100 and 365 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>100 and 365 days post-ASCT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 sequential dose escalation cohorts of AB-205</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AB-205</intervention_name>
    <description>Engineered human umbilical vein endothelial cells</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) who are candidates
             for HDT-ASCT with one of the following conditioning regimens:

               -  carmustine, etoposide, cytarabine, melphalan (BEAM)

               -  cyclophosphamide, carmustine, etoposide (CBV)

               -  thiotepa, busulphan, cyclophosphamide (TBC)

               -  additional myeloablative chemotherapy-based conditioning regimens may be
                  permitted with the approval of the medical monitor

          -  Adjunct radiation therapy to HDT will be allowed.

          -  Adequate organ function is required, defined as follows:

               -  Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia

               -  AST, ALT, and alkaline phosphatase &lt; 3 times the upper limit of normal

               -  Creatinine clearance ≥ 40 ml/min (calculated by Cockcroft Gault)

               -  LVEF ≥ 45% by MUGA or resting echocardiogram

               -  Pulmonary function (FEV1 and corrected DLCO) ≥ 45% predicted

               -  Adequate performance status ECOG ≤1

          -  For female subjects of childbearing potential:

               -  A negative serum or urine pregnancy test at screening.

               -  Subject must be willing to use a recommended method of contraception from the
                  start of the screening period and throughout the study period.

          -  For males who can father a child and are having intercourse with females of
             childbearing potential who are not using adequate contraception:

             - Subject must be willing to use a recommended method of contraception and refrain
             from sperm donation from the start of conditioning therapy for at least 1 year after
             completion and discussion with a treating physician.

          -  Willingness and ability to comply with scheduled visits, drug administration plan,
             protocol-specified laboratory tests, other study procedures, and study restrictions.

          -  Ability to provide written informed consent.

        EXCLUSION CRITERIA

          -  History of prior ASCT.

          -  Active malignancy other than the one for which the subject is undergoing HDT-ASCT.
             (Subjects with cervical carcinoma in situ or localized basal or squamous cell
             carcinoma treated with definitive surgery are eligible.)

          -  Subjects with a serious concomitant medical condition that could interfere with the
             conduct of the clinical trial, such as unstable angina, renal failure requiring
             hemodialysis, or active infection requiring IV antibiotics.

          -  Active Human Immunodeficiency Virus (HIV) infection and Acquired Immunodeficiency
             Syndrome (AIDS).

          -  Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed
             during treatment and for an additional 30 days or longer after chemotherapy treatment
             discontinuation if required by prescribing information for chemotherapy agents
             received during the study.

          -  Subjects who have known hypersensitivity reactions to bovine (cow) proteins or
             documented allergy to DMSO.

          -  Subject has other conditions that in the opinion of the investigator would place the
             subject at increased risk for toxicity by participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Kavalerchik, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiocrine Bioscience</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gayle Bresnahan</last_name>
    <phone>858-220-1046</phone>
    <email>gbresnahan@angiocrinebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Jaskowiak</last_name>
    <phone>408-646-2265</phone>
    <email>jjaskowiak@angiocrinebio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Rickard</last_name>
      <email>krickard@coh.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lam Nguyen</last_name>
      <email>lkng@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Mehrdad Abedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesika Reiner, MPH</last_name>
      <phone>858-822-5364</phone>
      <email>jreiner@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Mulroney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenai Wilmoth</last_name>
      <phone>415-353-2467</phone>
      <email>jenai.wilmoth@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Bita Fakhri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Care Center</last_name>
      <phone>800-865-1125</phone>
      <email>CancerAnswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Attaphol Pawarode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Scordo, MD</last_name>
      <phone>212-639-6052</phone>
    </contact>
    <investigator>
      <last_name>Michael Scordo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Channing V. Dudley, RN, BSN, MSN</last_name>
      <phone>615-875-8757</phone>
      <email>channing.v.dudley@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Bhagirathbhai Dholaria, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muzaffar Qazilbash, MD</last_name>
      <phone>713-745-3458</phone>
      <email>mqazilba@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Muzaffar Qazilbash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

